Pulmatrix (PULM) Coverage Initiated at HC Wainwright

Equities researchers at HC Wainwright assumed coverage on shares of Pulmatrix (NASDAQ:PULM) in a report issued on Friday, February 9th, Marketbeat.com reports. The brokerage set a “buy” rating and a $5.00 price target on the biotechnology company’s stock. HC Wainwright’s target price suggests a potential upside of 237.84% from the stock’s current price.

Separately, ValuEngine raised Pulmatrix from a “strong sell” rating to a “sell” rating in a research report on Friday, February 2nd.

Shares of Pulmatrix (NASDAQ PULM) traded down $0.05 on Friday, hitting $1.48. The stock had a trading volume of 327,120 shares, compared to its average volume of 749,039. Pulmatrix has a 12-month low of $1.35 and a 12-month high of $4.75.

An institutional investor recently raised its position in Pulmatrix stock. Vanguard Group Inc. grew its holdings in Pulmatrix Inc (NASDAQ:PULM) by 8.0% in the second quarter, according to its most recent disclosure with the SEC. The fund owned 99,758 shares of the biotechnology company’s stock after buying an additional 7,351 shares during the period. Vanguard Group Inc. owned 0.52% of Pulmatrix worth $240,000 at the end of the most recent reporting period. 19.95% of the stock is currently owned by hedge funds and other institutional investors.

TRADEMARK VIOLATION NOTICE: “Pulmatrix (PULM) Coverage Initiated at HC Wainwright” was originally reported by StockNewsTimes and is owned by of StockNewsTimes. If you are viewing this news story on another site, it was copied illegally and republished in violation of international trademark & copyright laws. The legal version of this news story can be read at https://stocknewstimes.com/2018/02/17/pulmatrix-pulm-now-covered-by-analysts-at-hc-wainwright.html.

Pulmatrix Company Profile

Pulmatrix, Inc is a clinical stage biopharmaceutical company developing inhaled therapies to address serious pulmonary disease. The Company’s product pipeline is focused on advancing treatments for rare diseases, including PUR1900, an inhaled anti-fungal for patients with lung disease, including cystic fibrosis.

Receive News & Ratings for Pulmatrix Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pulmatrix and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply